Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNN
A focus on liver disease, not addiction The Danish drug giant has been saying since at least last year that it doesn't plan to study semaglutide – which is also approved for weight loss as Wegovy – in areas like alcohol addiction, despite so many anecdotal reports like Ferguson's, and academic studies that are already underway. Novo Nordisk reiterated that stance Wednesday, noting that the main purpose of its new trial is to assess whether the medicines can improve liver health. Its primary measure is the medicines' effects on enhanced liver fibrosis, or scarring, over 28 weeks. “Secondary endpoints include safety and tolerability and changes in alcohol consumption,” a Novo Nordisk spokesperson said in an email. “There is a significant unmet medical need in alcohol-related liver disease, and the first line of treatment for the condition is lifestyle intervention to refrain from drinking alcohol.” The trial, first reported by Bloomberg News, aims to enroll about 240 participan
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity [CNBC]CNBC
- Semaglutide linked to reduced arthritis knee pain in people with obesity, study finds [MSNBC.com]MSNBC.com
- Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says [CNBC]CNBC
- Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [BNN Bloomberg (Canada)]BNN Bloomberg
- Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 8/8/24 - Beat
NVO
Sec Filings
- 10/28/24 - Form 6-K
- 10/21/24 - Form 6-K
- 10/21/24 - Form 6-K
- NVO's page on the SEC website